Home Cart Sign in  
Chemical Structure| 1403859-14-2 Chemical Structure| 1403859-14-2

Structure of CC-90001
CAS No.: 1403859-14-2

Chemical Structure| 1403859-14-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CC-90001 is an effective, selective, and orally active c-Jun N-terminal kinase (JNK) inhibitor that shows 12.9-fold selectivity for JNK1 over JNK2 in cell-based models, making it suitable for research on idiopathic pulmonary fibrosis.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CC-90001

CAS No. :1403859-14-2
Formula : C16H27N5O2
M.W : 321.42
SMILES Code : NC(C(C(N[C@H]1C[C@H]([C@@H](CC1)C)O)=N2)=CN=C2NC(C)(C)C)=O
MDL No. :MFCD33029314

Safety of CC-90001

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of CC-90001

MAPK
TLR

Isoform Comparison

Biological Activity

Description
CC-90001 is a potent, selective, and orally active inhibitor of c-Jun N-terminal kinase (JNK), showing 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. It can be employed in idiopathic pulmonary fibrosis research [1][2].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03958864 Healthy Volunteer PHASE1 COMPLETED 2019-06-13 Paraxel International, Glendal... More >>e, California, 91206, United States Less <<
NCT02510937 Pulmonary Fibrosis PHASE1 COMPLETED 2017-02-06 Tampa General Hospital, Tampa,... More >> Florida, 33606, United States|LaPorte County Institute for Clinical Research, Inc, Michigan City, Indiana, 46360, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|The Prince Charles Hospital, Chermside, 4032, Australia|St. Vincent's Hospital- Sydney, Darlinghurst, 2010, Australia Less <<
NCT03742882 Hepatic Impairment PHASE1 COMPLETED 2019-06-10 University of Miami Miller Sch... More >>ool of Medicine, Miami, Florida, 33136, United States|Orlando Clinical Research Center OCRC, Orlando, Florida, 32809, United States|Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, 37920, United States|The Texas Liver Institute, San Antonio, Texas, 78215, United States Less <<
NCT02321644 Healthy Subjects PHASE1 COMPLETED 2025-02-15 Covance-Daytona Beach, Daytona... More >> Beach, Florida, 32117, United States|TKL Research, Fair Lawn, New Jersey, 07410, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.11mL

0.62mL

0.31mL

15.56mL

3.11mL

1.56mL

31.11mL

6.22mL

3.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories